Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis

Company Overview

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is a clinical-stage biopharmaceutical company focused on developing therapies for women’s cancers, with an emphasis on hormone receptor-positive breast cancer. The company’s research is centered on oral endocrine medicines designed to target estrogen receptor signaling, an important driver of many breast tumors.

Olema’s lead product candidate is palazestrant, an investigational oral selective estrogen receptor degrader (SERD) being evaluated for the treatment of estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. The company is studying palazestrant as a potential treatment both on its own and in combination with other anticancer therapies.

Founded in 2013 and headquartered in San Francisco, Olema conducts drug discovery and clinical development activities through research programs and clinical studies intended to support regulatory approval in major international markets. As a clinical-stage company, its products remain investigational and are not yet approved for commercial use.

Key Stats

• Today's Range: $7.79 to $8.23
• 50-Day Range: $7.92 to $12.05
• 52-Week Range: $6.65 to $36.26
• Volume: 818,549 shs
• Average Volume: 1.34 million shs
• Market Capitalization: $694.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.60
• Consensus Rating: Moderate Buy

Olema Pharmaceuticals Stock Analysis - MarketRank™

Olema Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat, and ranked 463rd out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Olema Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Olema Pharmaceuticals has a consensus price target of $40.60, representing about 411.3% upside from its current price of $7.94.

Amount of Analyst Coverage

Olema Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.43) to ($2.72) per share.

Price to Book Value per Share Ratio

Olema Pharmaceuticals has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.00% of the float of Olema Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Olema Pharmaceuticals has a short interest ratio ("days to cover") of 15.93, which indicates bearish sentiment.

Change versus previous month

Short interest in Olema Pharmaceuticals has recently increased by 2.59%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Olema Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Olema Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Olema Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for OLMA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Olema Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Olema Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $144,750.00 in company stock.

Percentage Held by Insiders

12.56% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/07/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:OLMA
• CIK: 1750284
• Web: www.olema.com
• Phone: 650-243-5555
• Fax: N/A
• Employees: 150
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Olema Pharmaceuticals: $40.60
• High Price Target: $59.00
• Low Price Target: $27.00
• Potential Upside/Downside: +411.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.77
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$162.45 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -48.26%
• Return on Assets: -43.04%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 8.86
• Quick Ratio: 8.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.88 per share
• Price / Book: 1.35

Miscellaneous

• Outstanding Shares: 87,500,000
• Free Float: 76,508,000
• Market Cap: $694.75 million
• Optionable: Optionable
• Beta: 2.00